{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:35:43Z","timestamp":1792445743762,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118304","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:58:44Z","timestamp":1761433124000},"page":"118304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"P1","title":["Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: A multi-target approach to cancer therapy"],"prefix":"10.1016","volume":"302","author":[{"given":"Maryam A.Z.","family":"El-Attar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola S.","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azza","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine N.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan Mohamed","family":"Nomeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham A.","family":"Nematalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala F.","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.F.","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-6019","authenticated-orcid":false,"given":"Perihan A.","family":"Elzahhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayera W.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118304_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118304_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.apsb.2019.10.004","article-title":"Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent","volume":"10","author":"Jiang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118304_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117404","article-title":"Design and discovery of new selective and potent VEGF receptor 2 tyrosine kinase inhibitors","volume":"91","author":"Hou","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118304_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105334","article-title":"Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2","volume":"116","author":"Abou-Seri","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jmgm.2014.12.006","article-title":"Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2","volume":"56","author":"Wu","year":"2015","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2025.118304_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104532","article-title":"Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma","volume":"107","author":"Eissa","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.118304_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2478\/jvetres-2019-0030","article-title":"Significance of cyclooxygenase-2 in oncogenesis","volume":"63","author":"Szweda","year":"2019","journal-title":"J Vet Res"},{"key":"10.1016\/j.ejmech.2025.118304_bib10","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and cancer","volume":"85","author":"Brahimi-Horn","year":"2007","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118304_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/boc.201900099","article-title":"The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis","volume":"112","author":"Daunys","year":"2020","journal-title":"Biol. Cell"},{"key":"10.1016\/j.ejmech.2025.118304_bib12","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1111\/j.1582-4934.2008.00580.x","article-title":"Cyclooxygenase\u20102\/carbonic anhydrase\u2010IX up\u2010regulation promotes invasive potential and hypoxia survival in colorectal cancer cells","volume":"13","author":"Sansone","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118304_bib13","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.prp.2019.01.012","article-title":"Expression and association of carbonic anhydrase IX and cyclooxygenase-2 in colorectal cancer","volume":"215","author":"Tup\u00e1","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2025.118304_bib14","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.2174\/0929867327999200820173853","article-title":"The emerging role of COX-2, 15-LOX and PPAR\u03b3 in metabolic diseases and cancer: an introduction to novel multi-target directed ligands (MTDLs)","volume":"28","author":"Alaaeddine","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112439","article-title":"Expanding the anticancer potential of 1,2,3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases","volume":"200","author":"Elzahhar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105035","article-title":"Transforming iodoquinol into broad spectrum anti-tumor leads: repurposing to modulate redox homeostasis","volume":"113","author":"Chaaban","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108708","article-title":"Revisiting multi-pathway modulation with theophylline derivatives: targeting STAT3, NF-\u03baB, and apoptotic signaling in breast cancer","volume":"163","author":"Afifi","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1124\/molpharm.123.000704","article-title":"Thermogenic modulation of adipose depots: a perspective on possible therapeutic intervention with early cardiorenal complications of metabolic impairment","volume":"104","author":"El-Yazbi","year":"2023","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118304_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejmech.2018.11.061","volume":"163","author":"Eldehna","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113083","article-title":"Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1,2,3-triazole scaffold","volume":"211","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","article-title":"Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII","volume":"103","author":"Ibrahim","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115707","article-title":"Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties","volume":"259","author":"Saied","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/ph15111416","article-title":"Design, synthesis, molecular modeling, and anticancer evaluation of new VEGFR-2 inhibitors based on the Indolin-2-One scaffold","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118304_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108231","article-title":"New indolin-2-ones, possessing sunitinib scaffold as HDAC inhibitors and anti-cancer agents with potential VEGFR inhibition activity; design, synthesis and biological evaluation","volume":"156","author":"Yousefian","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113486","article-title":"Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail\/dual tail approaches: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies","volume":"221","author":"Eldeeb","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejmech.2019.06.081","article-title":"Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic\/phobic tails for targeting the middle region of human carbonic anhydrases active site: selective inhibitors of hCA IX","volume":"179","author":"Allam","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105920","article-title":"A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors","volume":"126","author":"Kumar","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/14756366.2017.1421181","article-title":"Novel [(3-indolylmethylene)hydrazono]indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation","volume":"33","author":"Eldehna","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib29","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1007\/s00044-011-9644-y","article-title":"Synthesis and antimicrobial activity of 5-chloroindoline-2,3-dione derivatives","volume":"21","author":"Shingade","year":"2012","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118304_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.127951","article-title":"Design, synthesis, biological activity, molecular docking and computational studies on novel 1,4-disubstituted-1,2,3-Triazole-Thiosemicarbazone hybrid molecules","volume":"1209","author":"Naveen","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118304_bib31","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118304_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2025.118304_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1749-8546-6-39","article-title":"Cytotoxic and apoptotic effects of six herbal plants against the human hepatocarcinoma (HepG2) cell line","volume":"6","author":"Machana","year":"2011","journal-title":"Chin. Med."},{"key":"10.1016\/j.ejmech.2025.118304_bib35","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1039\/D5MD00196J","article-title":"Recent advances in targeting COX-2 for cancer therapy: a review","volume":"16","author":"Kassab","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib36","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.apsb.2022.01.002","article-title":"Recent development on COX-2 inhibitors as promising anti-inflammatory agents: the past 10 years","volume":"12","author":"Ju","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118304_bib37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118304_bib38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/ijms23031328","article-title":"The apoptosis paradox in cancer","volume":"23","author":"Morana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118304_bib39","series-title":"Med Biochem","first-page":"791","article-title":"Apoptosis","author":"Blanco","year":"2017"},{"key":"10.1016\/j.ejmech.2025.118304_bib40","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1021\/acs.jmedchem.2c01408","article-title":"Inclusion of nitrofurantoin into the realm of cancer chemotherapy via biology-oriented synthesis and drug repurposing","volume":"66","author":"Elzahhar","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14776-0","article-title":"Novel benzylidene thiazolidinedione derivatives as partial PPAR\u03b3 agonists and their antidiabetic effects on type 2 diabetes","volume":"7","author":"Yasmin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118304_bib42","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: a webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118304_bib43","first-page":"6495","article-title":"Expression of matrix metalloproteinase-9, cyclooxygenase-2 and vascular endothelial growth factor are increased in gastrointestinal stromal tumors","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.118304_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5483\/BMBRep.2023-0150","article-title":"MMPP is a novel VEGFR2 inhibitor that suppresses angiogenesis via VEGFR2\/AKT\/ERK\/NF-\u03baB pathway","volume":"57","author":"Kim","year":"2024","journal-title":"BMB Rep."},{"key":"10.1016\/j.ejmech.2025.118304_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0323635","article-title":"Carbonic anhydrase IX downregulation linked to disruption of HIF-1, NF\u03baB and STAT3 pathways as a new mechanism of ibuprofen anti-cancer effect","volume":"20","author":"Grossmannova","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118304_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijpharm.2008.05.001","article-title":"In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors","volume":"361","author":"Konsoula","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2025.118304_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-017-02794-5","article-title":"Epigenetic modulation of inflammation and synaptic plasticity promotes resilience against stress in mice","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118304_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114343","article-title":"Pyrazolones as inhibitors of immune checkpoint blocking the PD-1\/PD-L1 interaction","volume":"236","author":"Le Biannic","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117415","article-title":"Novel thiazolones for the simultaneous modulation of PPAR\u03b3, COX-2 and 15-LOX to address metabolic disease-associated portal inflammation","volume":"289","author":"El-Shoukrofy","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/17460441.2.4.469","article-title":"Ligand efficiency indices for effective drug discovery","volume":"2","author":"Abad-Zapatero","year":"2007","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118304_bib51","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1016\/j.bmcl.2013.04.086","article-title":"The development of CNS-active LRRK2 inhibitors using property-directed optimisation","volume":"23","author":"Kavanagh","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118304_bib52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118304_bib53","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118304_bib54","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/acsptsci.5c00011","article-title":"Multi-target glitazones for modulating peroxisome proliferator-activated Receptor-\u03b3, Cyclooxygenase-2, and carbonic anhydrases for the management of metabolic dysfunction","volume":"8","author":"Elzahhar","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118304_bib55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bioorg.2018.12.040","article-title":"Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis","volume":"85","author":"Mohamed","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106273","article-title":"Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR\/Topo-1 inhibition","volume":"131","author":"Halim","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116098","article-title":"Inhibition of carbonic anhydrase IX promotes apoptosis through intracellular pH level alterations in cervical cancer cells","volume":"22","author":"Temiz","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118304_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ejmech.2015.12.035","article-title":"A comparison of novel organoiridium(III) complexes and their ligands as a potential treatment for prostate cancer","volume":"109","author":"Hockey","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00044-021-02716-7","article-title":"Design and synthesis of new 1,4,5-trisubstituted triazole-bearing benzenesulphonamide moiety as selective COX-2 inhibitors","volume":"30","author":"Bekheit","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118304_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116138","article-title":"Chromone-based small molecules for multistep shutdown of arachidonate pathway: simultaneous inhibition of COX-2, 15-LOX and mPGES-1 enzymes","volume":"266","author":"Elzahhar","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib61","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14756366.2021.1887169","article-title":"Challenging inflammatory process at molecular, cellular and in vivo levels via some new pyrazolyl thiazolones","volume":"36","author":"Elzahhar","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/bmc.3370","article-title":"Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives","volume":"29","author":"Sharma","year":"2015","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejmech.2025.118304_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/07388551.2015.1128876","article-title":"Flow cytometry: basic principles and applications","volume":"37","author":"Adan","year":"2017","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118304_bib64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.ejmech.2025.118304_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108392","article-title":"Exploring Thieno\/Furo[2,3-b]pyridines as new scaffolds for potential FAK inhibition: design, synthesis, biological evaluation and in silico studies","volume":"159","author":"Ismail","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2201403","article-title":"Effect of hydrophobic extension of aryl enaminones and pyrazole-linked compounds combined with sulphonamide, sulfaguanidine, or carboxylic acid functionalities on carbonic anhydrase inhibitory potency and selectivity","volume":"38","author":"Allam","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/492173","article-title":"Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling","volume":"2014","author":"Choi","year":"2014","journal-title":"Mediat. Inflamm."},{"issue":"1 7","key":"10.1016\/j.ejmech.2025.118304_bib69","first-page":"1","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118304_bib70","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118304_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77327-0","article-title":"Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models","volume":"10","author":"Siramshetty","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118304_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106874","article-title":"New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: synthesis, anticancer evaluation, and molecular modeling studies","volume":"141","author":"Hawas","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115333","article-title":"Modulating leishmanial pteridine metabolism machinery via some new coumarin-1,2,3-triazoles: design, synthesis and computational studies","volume":"253","author":"Hassan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118304_bib74","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13065-023-00944-z","article-title":"Insights on the in-vitro binding interaction between donepezil and bovine serum albumin","volume":"17","author":"El Gammal","year":"2023","journal-title":"BMC Chem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425010694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:37:16Z","timestamp":1764625036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425010694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":73,"alternative-id":["S0223523425010694"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118304","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Click-modifiable isatin hydrazones as COX-2, VEGFR-2, and carbonic anhydrase inhibitors: A multi-target approach to cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118304"}}